Ultragenyx Pharmaceutical Inc  

(Public, NASDAQ:RARE)   Watch this stock  
Find more results for RARE
+2.63 (4.40%)
Real-time:   10:15AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 60.12 - 62.92
52 week 32.02 - 70.69
Open 60.22
Vol / Avg. 22,953.00/337,634.00
Mkt cap 2.24B
P/E     -
Div/yield     -
EPS -2.33
Shares 35.60M
Beta     -
Inst. own 86%
Jun 18, 2015
Ultragenyx Pharmaceutical Inc Annual Shareholders Meeting - 7:00PM EDT - Add to calendar
May 11, 2015
Q1 2015 Ultragenyx Pharmaceutical Inc Earnings Release (Estimated) Add to calendar
Mar 25, 2015
Q4 2014 Ultragenyx Pharmaceutical Inc Earnings Call - Webcast
Mar 25, 2015
Q4 2014 Ultragenyx Pharmaceutical Inc Earnings Release
Mar 11, 2015
Ultragenyx Pharmaceutical Inc at Barclays Healthcare Conference - Webcast
Mar 3, 2015
Ultragenyx Pharmaceutical Inc at Cowen Health Care Conference
Feb 23, 2015
Ultragenyx Pharmaceutical Inc at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -32.84% -46.43%
Return on average equity -34.94% -117.34%
Employees 107 -
CDP Score - -


60 Leveroni Ct
NOVATO, CA 94949-5746
United States - Map
+1-415-4838800 (Phone)
+1-415-4838810 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ultragenyx Pharmaceutical Inc. is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company focuses on diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. The Company�s pipeline product categories include biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. The Company�s products in a Phase II study development includes KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM.

Officers and directors

Eran Nadav Ph.D. Chairman of the Board
Age: 44
Bio & Compensation  - Reuters
Emil D. Kakkis M.D., Ph.D. President, CEO, Board Member
Bio & Compensation  - Reuters
Shalini Sharp Senior Vice President & CFO
Age: 39
Bio & Compensation  - Reuters
Sunil Agarwal M.D. Chief Medical Officer, Senior Vice President
Bio & Compensation  - Reuters
Steven Jungles Senior VP, Technology
Age: 48
Bio & Compensation  - Reuters
Thomas Kassberg Senior Vice President, Chief Business Officer
Age: 53
Bio & Compensation  - Reuters
Michael P. Cohrs Ph.D. Vice President - Quality
Age: 53
Bio & Compensation  - Reuters
John Ditton Vice President - Commercial Planning
Age: 49
Bio & Compensation  - Reuters
Tony Koutsoukos Ph.D. Vice President - Biometrics
Age: 54
Bio & Compensation  - Reuters
Cordelia Leonard Vice President - Regulatory Affairs and Quality Assurance
Age: 53
Bio & Compensation  - Reuters